BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cancer Genetics, Inc. and Aptiv Solutions Form Strategic Partnership Focused on Creating More Effective Clinical Trials in Oncology


3/24/2011 9:10:50 AM

RUTHERFORD, NJ--(Marketwire - March 23, 2011) - Cancer Genetics, Inc. (CGI) and Aptiv Solutions have formed a strategic partnership focused on delivering comprehensive solutions to biopharmaceutical and medical device firms conducting clinical trials for oncology therapeutics. CGI provides disease-specific biomarker knowledge, proprietary molecular testing and oncology lab services to sponsor companies during the early stages of clinical trials. Aptiv Solutions provides a portfolio of innovative services including adaptive trial design, early phase product strategy, regulatory services, pharmacovigilance, and the operational support of a global clinical research organization.

Together, CGI and Aptiv Solutions will provide biopharmaceutical firms with a better understanding of modes of action of a variety of therapeutics and the role for biomarkers in the oncology drug development process. Early insight in complex diseases and complicated patients garnered by using genomic technologies and other methodologies will drive informed decisions and successful development of targeted therapies, personalized medicine and other new therapeutics. The collaboration will provide customers with the products and services necessary to bring oncology therapeutics to their patients faster and at a reduced cost.

"Integrated clinical information is critical to providing customized patient treatment in which drug usage and dosage can be specifically targeted to the individual patient's genetic requirement," said Panna Sharma, Chief Executive Officer of CGI. "As a leader in personalized medicine, CGI is confident that this collaboration will assist our clients in the development of new therapeutics and diagnostics by reducing the time frame and costs for regulatory approval through patient stratification."

"We are excited about partnering with CGI to enhance our ability to offer molecular and genetic laboratory expertise to our clients," said Gene Resnick, MD, Chief Medical Officer for Aptiv Solutions. "We recognize the critical role of biomarkers in the development of new agents in oncology and other therapeutic areas, and look forward to bringing a combined solution to the pharmaceutical, biotech and medical device industries which will enable clients to accelerate the progress of more efficient clinical trials. Adding this capacity to our existing expertise in oncology trial management will bring a value-add for sponsors and ultimately for patients."

About CGI
Based in of Rutherford, NJ, CGI was founded by Dr. R.S.K. Chaganti in 1999 and has become an emerging leader in personalized cancer treatment. CGI's synergistic business model provides cancer-focused diagnostic testing services to leading oncologists, pathologists, hospitals, and academic centers as well as the development of next-generation diagnostic products that leverage CGI's unique IP in molecular genetics and oncology. Products developed by CGI are revolutionizing the management and treatment of certain cancers while reducing healthcare costs. Information about the company can be found on the Internet at: www.cancergenetics.com.

About Aptiv Solutions
Aptiv Solutions is a global biopharmaceutical and medical device development services organization, focused on recognizing, understanding and enabling clients to capitalize on rapid and fundamental changes they face in developing products in the pharmaceutical, biotech and medical device market. Aptiv Solutions integrates the resources and expertise of six recently merged companies: Averion International, Trio Clinical Research, Fulcrum Pharma, ClinResearch, Niphix and ADDPLAN.

The Aptiv Solutions legacy companies, Averion International, Trio Clinical Research, ClinResearch, and Niphix have conducted hundreds of oncology trials in both the drug and device areas at thousands of clinical sites with hundreds of thousands of patients. Aptiv Solutions provides innovative, comprehensive and proven product development capabilities, built on an extensive portfolio of services and a worldwide team of more than 700 professionals. Additional information: www.aptivsolutions.com.


Contact:
Panna Sharma
(201) 528-9191
Email Contact



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES